Clinical Trials
NIH Conducts Clinical Trial of The mRNA Nipah Virus Jab
An early-stage clinical trial assessing an investigational vaccine to stave off Nipah virus infection has been started by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Produced by Moderna, Inc....
Clinical Trials
Bharat Biotech Ends Clinical Trial Of Nasal COVID-19 Vaccine
The clinical phase III trials of the COVID-19 nasal vaccination have been finished, according to the Chairman and Managing Director of Bharat Biotech, Dr. Krishna Ella, who stated the company will submit its data to the Drugs Controller General...
Clinical Trials
Phesi global analysis of 2.5 million patients finds participants in breast cancer clinical trials are getting younger
New analysis from Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has found that since 2014 the number of women younger than 60 years of age participating in breast cancer clinical trials has increased...
Clinical Trials
Calyx Selected by ProTrials as Partner for Improving Clinical Trial Outcomes Data
Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced it has been named an approved partner by ProTrials Research, Inc., a mid-sized full-service clinical research organization (CRO) specializing...
Clinical Trials
Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health
Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have announced a collaboration on a virtual clinical trial...
Clinical Trials
IQVIA selected to accelerate clinical development of VYVGART by argenx SE
IQVIA announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis...
Clinical Trials
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Biohaven Pharmaceutical Holding Company Ltd. announced that it entered into a worldwide license agreement with Bristol Myers Squibb for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin. Taldefgrobep is the third development asset...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read